KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Globus Medical (GMED) EBIT (2016 - 2025)

Globus Medical's EBIT history spans 15 years, with the latest figure at $169.3 million for Q4 2025.

  • For Q4 2025, EBIT rose 180.95% year-over-year to $169.3 million; the TTM value through Dec 2025 reached $479.8 million, up 189.06%, while the annual FY2025 figure was $479.8 million, 189.06% up from the prior year.
  • EBIT reached $169.3 million in Q4 2025 per GMED's latest filing, up from $137.4 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $169.3 million in Q4 2025 to a low of $404000.0 in Q3 2023.
  • Average EBIT over 5 years is $58.9 million, with a median of $54.3 million recorded in 2021.
  • Peak YoY movement for EBIT: plummeted 99.32% in 2023, then skyrocketed 11805.45% in 2024.
  • A 5-year view of EBIT shows it stood at $18.2 million in 2021, then surged by 196.86% to $54.0 million in 2022, then plummeted by 81.26% to $10.1 million in 2023, then soared by 495.42% to $60.3 million in 2024, then soared by 180.95% to $169.3 million in 2025.
  • Per Business Quant, the three most recent readings for GMED's EBIT are $169.3 million (Q4 2025), $137.4 million (Q3 2025), and $76.1 million (Q2 2025).